DBV TECHNOLOGIES SA (DBV.PA) Stock Fundamental Analysis

EPA:DBV • FR0010417345

3.46 EUR
+0.03 (+0.87%)
Last: Feb 17, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

3

Overall DBV gets a fundamental rating of 3 out of 10. We evaluated DBV against 78 industry peers in the Biotechnology industry. DBV may be in some trouble as it scores bad on both profitability and health. DBV is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year DBV has reported negative net income.
  • In the past year DBV has reported a negative cash flow from operations.
  • DBV had negative earnings in each of the past 5 years.
  • In the past 5 years DBV always reported negative operating cash flow.
DBV.PA Yearly Net Income VS EBIT VS OCF VS FCFDBV.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

  • With a Return On Assets value of -85.56%, DBV is not doing good in the industry: 71.79% of the companies in the same industry are doing better.
  • The Return On Equity of DBV (-142.22%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROIC N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
DBV.PA Yearly ROA, ROE, ROICDBV.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • Looking at the Gross Margin, with a value of 91.34%, DBV belongs to the top of the industry, outperforming 88.46% of the companies in the same industry.
  • DBV's Gross Margin has declined in the last couple of years.
  • DBV does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 91.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
DBV.PA Yearly Profit, Operating, Gross MarginsDBV.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K -2.5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • DBV does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, DBV has more shares outstanding
  • The number of shares outstanding for DBV has been increased compared to 5 years ago.
  • DBV has a worse debt/assets ratio than last year.
DBV.PA Yearly Shares OutstandingDBV.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DBV.PA Yearly Total Debt VS Total AssetsDBV.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • DBV has an Altman-Z score of -1.18. This is a bad value and indicates that DBV is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -1.18, DBV is doing worse than 64.10% of the companies in the same industry.
  • A Debt/Equity ratio of 0.08 indicates that DBV is not too dependend on debt financing.
  • DBV has a better Debt to Equity ratio (0.08) than 67.95% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Altman-Z -1.18
ROIC/WACCN/A
WACC8.06%
DBV.PA Yearly LT Debt VS Equity VS FCFDBV.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M

2.3 Liquidity

  • DBV has a Current Ratio of 2.45. This indicates that DBV is financially healthy and has no problem in meeting its short term obligations.
  • DBV's Current ratio of 2.45 is in line compared to the rest of the industry. DBV outperforms 53.85% of its industry peers.
  • A Quick Ratio of 2.45 indicates that DBV has no problem at all paying its short term obligations.
  • DBV's Quick ratio of 2.45 is in line compared to the rest of the industry. DBV outperforms 58.97% of its industry peers.
Industry RankSector Rank
Current Ratio 2.45
Quick Ratio 2.45
DBV.PA Yearly Current Assets VS Current LiabilitesDBV.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • DBV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.66%, which is quite impressive.
  • Looking at the last year, DBV shows a very strong growth in Revenue. The Revenue has grown by 224.69%.
  • The Revenue has been growing slightly by 0.50% on average over the past years.
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A

3.2 Future

  • DBV is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.26% yearly.
  • DBV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 75.93% yearly.
EPS Next Y-36.93%
EPS Next 2Y-9.86%
EPS Next 3Y24.97%
EPS Next 5Y16.26%
Revenue Next Year-55.09%
Revenue Next 2Y271.45%
Revenue Next 3Y438.04%
Revenue Next 5Y75.93%

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
DBV.PA Yearly Revenue VS EstimatesDBV.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B
DBV.PA Yearly EPS VS EstimatesDBV.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • DBV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year DBV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DBV.PA Price Earnings VS Forward Price EarningsDBV.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
DBV.PA Per share dataDBV.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as DBV's earnings are expected to grow with 24.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-9.86%
EPS Next 3Y24.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for DBV!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

DBV TECHNOLOGIES SA

EPA:DBV (2/17/2026, 7:00:00 PM)

3.46

+0.03 (+0.87%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-28
Earnings (Next)03-23
Inst Owners69.74%
Inst Owner ChangeN/A
Ins Owners0.1%
Ins Owner ChangeN/A
Market Cap190.16M
Revenue(TTM)15.73M
Net Income(TTM)-122.55M
Analysts80
Price Target5.96 (72.25%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)16.21%
PT rev (3m)50.39%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-16.4%
EPS NY rev (3m)5.03%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 59.32
P/FCF N/A
P/OCF N/A
P/B 2.62
P/tB 2.62
EV/EBITDA N/A
EPS(TTM)-0.64
EYN/A
EPS(NY)-0.77
Fwd EYN/A
FCF(TTM)-1.35
FCFYN/A
OCF(TTM)-1.35
OCFYN/A
SpS0.06
BVpS1.32
TBVpS1.32
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -85.56%
ROE -142.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 91.34%
FCFM N/A
ROA(3y)-84.27%
ROA(5y)-75.7%
ROE(3y)-172.64%
ROE(5y)-138.93%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.75%
GM growth 5Y-2.02%
F-Score2
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.08
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 42.61%
Cap/Sales 8.26%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.45
Quick Ratio 2.45
Altman-Z -1.18
F-Score2
WACC8.06%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)25.42%
Cap/Sales(5y)23.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-36.93%
EPS Next 2Y-9.86%
EPS Next 3Y24.97%
EPS Next 5Y16.26%
Revenue 1Y (TTM)224.69%
Revenue growth 3Y11.73%
Revenue growth 5Y0.5%
Sales Q2Q%N/A
Revenue Next Year-55.09%
Revenue Next 2Y271.45%
Revenue Next 3Y438.04%
Revenue Next 5Y75.93%
EBIT growth 1Y-31.77%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-9.76%
EBIT Next 3Y32.47%
EBIT Next 5YN/A
FCF growth 1Y0.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y0.02%
OCF growth 3YN/A
OCF growth 5YN/A

DBV TECHNOLOGIES SA / DBV.PA FAQ

What is the fundamental rating for DBV stock?

ChartMill assigns a fundamental rating of 3 / 10 to DBV.PA.


What is the valuation status of DBV TECHNOLOGIES SA (DBV.PA) stock?

ChartMill assigns a valuation rating of 1 / 10 to DBV TECHNOLOGIES SA (DBV.PA). This can be considered as Overvalued.


Can you provide the profitability details for DBV TECHNOLOGIES SA?

DBV TECHNOLOGIES SA (DBV.PA) has a profitability rating of 1 / 10.


Can you provide the financial health for DBV stock?

The financial health rating of DBV TECHNOLOGIES SA (DBV.PA) is 3 / 10.